Duke Breast Cancer Expert Named One of TIME’s 100 Most Influential People for 2016

Contact: Samiha KhannaPhone: 919-419-5069Email: samiha.khanna@duke.eduhttps://www.dukehealth.org FOR IMMEDIATE RELEASE on Thursday, April 21, 2016 DURHAM, N.C. -- Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute, has been named one of TIME’s 100 most influential people for 2016 as a pioneer in her field. One of the world’s foremost experts in early-stage breast cancers, Hwang has become an international leader calling for research to guide treatment for ductal carcinoma in situ (DCIS), in which abnormal cells are detected in the lining of a milk duct, but haven’t spread to other tissues. DCIS is the most common form of non-invasive breast cancer in the U.S., and accounts for about 20 percent of all new breast cancer cases diagnosed from mammogram screenings. But doctors are divided on how some patients with low-risk DCIS should be treated. Hwang’s research and advocacy for a more informed approach to DCIS treatments -- which could include lumpectomy and/or ongoing surveillance instead of aggressive radiation or mastectomy -- has helped spur international discussion. She has been a voice for women who are diagnosed with DCIS to receive the best treatment available while sparing them unnecessary procedures that don’t help, or may even cause harm. Hwang and fellow breast cancer surgeon Laura J. Esserman, M.D., MBA, of the University of California, San Francisco, share the honor in TIME, written by musician and breast cancer ...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

In this study, we sought to evaluate the outcomes for patients diagnosed with DCIS treated using accelerated whole breast RT and concomitant lumpectomy boost following breast conserving surgery.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
Author Affiliations open 1Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, USA 2Social &Scientific Systems, Inc., Durham, North Carolina, USA 3Westat, Durham, North Carolina, USA 4Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway 5Biostatistics and Computational Biology Branch, NIEHS, NIH, DHHS, Research Triangle Park, North Carolina, USA PDF Version (548 KB) Abstract About This Article Supplemental Material Bac...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Conclusions: Although further work is required to confirm our results and to clarify potential mechanisms, our findings suggest that exposure to residential outdoor light at night may contribute to invasive breast cancer risk. https://doi.org/10.1289/EHP935 Received: 08 August 2016 Revised: 17 March 2017 Accepted: 20 March 2017 Published: 17 August 2017 Address correspondence to P. James, 401 Park Dr., 3rd Floor West, Boston, MA 02215 USA. Telephone: (617) 525-2567; Email: pjames@hsph.harvard.edu Supplemental Material is available online (https://doi.org/10.1289/EHP935). The authors declare they have no actual or pot...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Conclusions: In this prospective study, using an indoor wood-burning stove/fireplace in the longest adult residence at least once a week and burning either wood or natural gas/propane was associated with a modestly higher risk of breast cancer. https://doi.org/10.1289/EHP827 Received: 18 July 2016 Revised: 16 November 2016 Accepted: 09 December 2016 Published: 18 July 2017 Address correspondence to A.J. White, Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709-2233 USA. Telephone: (919) 316-4867. Email: alexandra.white@nih.gov Supp...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
SummaryDuring the San Antonio Breast Cancer Symposium in December 2016, the main topics were systemic treatment of breast cancer and molecular research. But several studies were also presented concerning local therapy: Surgical issues on evaluating resection margins, management of ductal carcinoma in situ (DCIS), surgical challenges after neoadjuvant therapy related to assessment of response or treatment of axillary lymph nodes, and studies about outcome after breast reconstruction and radiation therapy were discussed. In this short review, oral presentations of these topics are summarized.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Adjuvant hypofractionated whole breast radiation therapy (WBRT) for early stage breast cancer has become a standard treatment regimen because of its equivalent efficacy, attractive cost, and convenience. Randomized clinical trials have shown hypofractionated regimen to have equivalent local control to conventional fractionation for patients with invasive breast cancer, but few studies in the United States have reported results of hypofractionated WBRT to treat DCIS.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
ConclusionER+/PR- subtype was not a significant predictor of recurrence in DCIS patients. This finding is in contrast to the risk of recurrence and tumor aggressiveness seen in invasive breast cancers. Mastectomy and post lumpectomy radiation were associated with improved outcomes as was adjuvant endocrine therapy.Citation Format: Chaudhary LN, Jawa Z, Hanif A, Szabo A, Chitambar CR. Ductal carcinoma in situ: Patient outcomes and association with hormone receptors [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Ca...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: The combination of ONT-380 and trastuzumab is feasible. The combination has an acceptable safety profile with low incidence and severity of diarrhea and rash. Transaminase elevation was asymptomatic for all pts and resolved with drug interruption/delay. Preliminary evidence of activity was observed in CNS and non-CNS disease.Citation Format: Coe AM, Trivedi MS, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San An...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
The oldest local approach to breast cancer prevention is surgery. The largest and most rigorous description of this procedure in a high risk population comes from the Mayo Clinic, where 639 women underwent bilateral mastectomy for prevention between 1960 and 1993. Of these procedures, 90% were subcutaneous mastectomies, i.e. ∼90% of the breast was removed, with preservation of the nipple and areola. The breast cancer incidence in this population, with 13 year follow-up, was 90% of the expected incidence. A subset was tested for BRCA1/2 mutations, and among 26 mutations carriers, no cancers were observed. Subsequent stu...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Invited Speaker Abstracts Source Type: research
We report the design and synthesis of ZB716, a C-3 position boronic acid modified fulvestrant, which behaves as a steroidal SERD suitable for oral administration. ZB716 binds to ERa competitively at an IC50 of 4.1 nM as compared to 3.9 nM for fulvestrant, and it effectively downregulates ERa (IC50=12.7 nM) in both tamoxifen-sensitive (T47D) and tamoxifen-resistant (T47D/PKCa) breast cancer cells. It acts as an antiestrogen that exerts potent antiproliferative effects on tamoxifen-resistant breast cancer cells (MCF-7/TamR, T47D/PKCa, and T47D/Y537S). When orally administered to mice, rats, and Beagle dogs, ZB716 demonstrate...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Breast Carcinoma | Breast Lumpectomy | Breast Surgery | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Clinical Trials | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Environmental Health | Health | Hormones | Lumpectomy | Mammography | Mastectomy | Oral Cancer | Pediatrics | Study | Women